Hyperbilirubinemia Guideline
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Equipment*Packet:*Bililights(And
Equipment*Packet:*Bililights(and(Phototherapy* UMDNS(#:(17515(( Date*of*Creation:(November(10,(2015( Creator:(Complied(by(Cassandra(Stanco(for*Engineering(World(Health((EWH)* * * Equipment*Packet*Contents:* This(packet(contains(information(about(the(operation,(maintenance,(and(repair(of(bililights( and(bilirubinometers.( ( Part*I:*External*From*the*Packet:* * 1. An*Introduction*to*Bililights:*(PowerPoint( * Part*II:*Included*in*this*Packet:* * 1. Operation*and*Use:* a. Brief(Introduction(to(Phototherapy((p.(3)( b. Brief(Introduction(to(Bilirubinometers((p.(4)( c. Introduction(to(Neonatal(Jaundice((p.(5P12)( d. Operation(and(Use(of(Phototherapy(Lights((p.(13P14)( 2. Diagrams*and*Schematics:* a. Figure(1:((WHO(Specification(for(Bilirubinometer((p.16P18)( 3. Preventative*Maintenance*and*Safety:* a. Bililight(Preventative(Maintenance((p.(20)* b. Preventative(Maintenance(Table(for(Lights((p.(21)* 4. Troubleshooting*and*Repair:** a. Bililight(Repair(and(Troubleshooting(Flowchart((p.(23P24)* b. Lights(Troubleshooting(Table((p.(25)* 5. Resources*for*More*Information* a. Resources(for(More(Information((p.(27)* b. Bibliography((p.(28)* * ( * * * * * * 1.*Operation*and*Use*of*Bililights* * * * Featured*in*this*Section:* * * * Malkin,(Robert.(“Phototherapy(Lights.”(Medical&Instrumentation&in&the&Developing&World.(Engineering( World(Health,(2006.(( * ( WHO.(“Bilirubinometer.”(From(the(publication:(Core&Medical&Equipment.(Geneva,(Switzerland,(2011.( ( ( WHO.(“Phototherapy(units,(hyperbilirubinemia.”(From(the(page:(“Hospital(medical(equipment:(Data( -
Zaporizhzhya State Medical University Department of Hospital Pediatrics
Zaporizhzhya State Medical University Department of hospital pediatrics The collection of lectures on neonatology for the fifth year English-speaking medical students of international faculty delivered at the department of Hospital pediatrics 2016 2 The collection of lectures on neonatology which are delivering at the department of Hospital pediatrics for 5th year English-speaking students was prepared in accordance to the 5th year curriculum on Pediatrics. The specified illustrated collection is published for the first time and includes 5 lectures on basic problems of neonatology. The collection designed for the effective preparation of teachers for lectures delivered at the department of hospital pediatrics of Zaporizhzhya State Medical University, TEMATIC PLAN OF LECTURES ON NEONATOLOGY # Topic Amount od hours 1 Perinatal asphyxia. 2 2 Birth trauma of newborns. 2 3 RDS in newborns. 2 4 Origin, differential diagnosis and therapy of jaundices in 2 newborns 5 TORCH - infections in newborns. 2 Compilers: Lezhenko G.O. – the Head of Hospital pediatrics department, professor, medical sciences doctor Reznichenko J.G. - professor of Hospital pediatrics department, medical sciences doctor. Kamenshchyk A.V. – associate professor of Hospital pediatrics department, medical sciences candidate. Vrublevska S.V. – assistant professor of Hospital pediatrics, medical sciences candidate. Lebedinets O.M. - – assistant professor of Hospital pediatrics, medical sciences candidate. Gladun E.V. - assistant professor of Hospital pediatrics, medical sciences candidate. Developing establishment: Zaporizhzhya State Medical University The collection of lectures ratified on the meeting of Central Methodical Council of Zaporizhzhya Sate Medical University/ Protocol #_______from________________________ 3 УДК: 616-053.31(042)=111 ББК: 57.3Я73 T-44 Г.О. Леженко, Ю.Г. -
CPG Management of Neonatal Jaundice
Management of Neonatal Jaundine (Second Edition) Published by: Malaysia Health Technology Assessment Section (MaHTAS) Medical Development Division, Ministry of Health Malaysia Level 4, Block E1, Precinct 1 Federal Government Administrative Centre 62590, Putrajaya, Malaysia Copyright The copyright owner of this publication is MaHTAS. Content may be reproduced in any number of copies and in any format or medium pro- vided that a copyright acknowledgement to MaHTAS is included and the content is not changed, not sold, nor used to promote or endorse any product or service, and not used in an inappropriate or misleading context. ISBN: 978-967-0769-12-7 Available on the following websites: http://www.moh.gov.my http://www.acadmed.org.my http://www.mpaweb.org.my http://www.perinatal-malaysia.org Also available as an app for Android and iOS Platform: MyMaHTAS STATEMENT OF INTENT These clinical practice guidelines (CPG) are meant to be guides for clinical practice, based on the best available evidence at the time of development. Adherence to these guidelines may not necessarily guarantee the best outcome in every case. Every healthcare provider is responsible for the management of his/her unique patient based on the clinical picture presented by the patient and the management options available locally. These guidelines were issued in 2014 and will be reviewed in 2018 or sooner if new evidence becomes available. When it is due for updating, the Chairman of the CPG or National Advisor of the related specialty will be informed about it. A discussion will be done on the need for a revision including the scope of the revised CPG. -
Hilary Lumsden Debbie Holme
This page intentionally left blank Edited By Hilary Lumsden RN RM BSC(HONS) MSC RMT ENB 405 Senior Lecturer in Midwifery, University of Wolverhampton; and External Examiner, University of Sheffield Debbie Holmes RN RM BSC(HONS) PCGE (HE) Senior Lecturer in Midwifery, University of Wolverhampton; and External Examiner, King’s College, London First published in Great Britain in 2010 by Hodder Arnold, an imprint of Hodder Education, an Hachette UK Company 338 Euston Road, London NW1 3BH http://www.hodderarnold.com © 2010 Hodder Arnold (Publishers) Ltd All rights reserved. Apart from any use permitted under UK copyright law, this publication may only be reproduced, stored or transmitted, in any form, or by any means with prior permission in writing of the publishers or in the case of reprographic production in accordance with the terms of licences issued by the Copyright Licensing Agency. In the United Kingdom such licences are issued by the Copyright Licensing Agency: Saffron House, 6–10 Kirby Street, London EC1N 8TS. Whilst the advice and information in this book are believed to be true and accurate at the date of going to press, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. In particular (but without limiting the generality of the preceding disclaimer) every effort has been made to check drug dosages; however it is still possible that errors have been missed. Furthermore, dosage schedules are constantly being revised and new side-effects recognized. For these reasons the reader is strongly urged to consult the drug companies' printed instructions before administering any of the drugs recommended in this book. -
Mortality in Preterm Infants with Respiratory Distress Syndrome Treated with Poractant Alfa, Calfactant Or Beractant: a Retrospective Study
Journal of Perinatology (2013) 33, 119–125 r 2013 Nature America, Inc. All rights reserved. 0743-8346/13 www.nature.com/jp ORIGINAL ARTICLE Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study R Ramanathan1, JJ Bhatia2, K Sekar3 and FR Ernst4 1LAC þ USC Medical Center and Children’s Hospital Los Angeles, Los Angeles, CA, USA; 2Division of Neonatology, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA, USA; 3Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA and 4Premier Research Services, Premier healthcare alliance, Charlotte, NC, USA infant deaths in 2005 and was the second leading cause of infant Objective: The objective of this study is to compare all-cause in-hospital mortality.2 Respiratory distress syndrome (RDS) is the most mortality in preterm infants with respiratory distress syndrome (RDS) common cause of respiratory distress in preterm infants and occurs treated with poractant alfa, calfactant or beractant. in nearly 50% of preterm infants born at less than 30 weeks of 3 Study Design: A retrospective cohort study of 14 173 preterm infants gestation. with RDS, treated with one of three surfactants between 2005 and 2009, Treatment with surfactant for RDS has been shown to using the Premier Database was done. Multilevel, multivariable logistic significantly decrease pneumothorax, and neonatal and infant 3–8 regression modeling, adjusting for patient- and hospital-level factors was mortality. The animal-derived surfactants, poractant alfa performed. (Curosurf, Chiesi Farmaceutici SpA, Parma, Italy), calfactant (Infasurf, Ony, St Louis, MO, USA) and beractant (Survanta, Abbott Result: Calfactant treatment was associated with a 49.6% greater Nutrition, Columbus, OH, USA) have been shown to be associated likelihood of death than poractant alfa (odds ratio (OR): 1.496, 95% with greater early improvement in the requirement for ventilatory confidence interval (CI): 1.014–2.209, P ¼ 0.043).